Recruiting LYell SYndrome MEsenchymal Stromal Cells Treatment NCT04711200 Conditions Adipose Derived Stromal Cells, Chemically-Induced Disorders, Dermatitis, +20 more Locations Henri Mondor — Créteil, France View Trial Details
Recruiting Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis NCT06119490 Conditions Chemically-Induced Disorders, Dermatitis, Drug Eruptions, +15 more Locations Department of Dermatology, the First Affiliated Hospital of Fujian Medical University. — Fuzhou, Fujian, China View Trial Details
Not Yet Recruiting New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. NCT07110662 Conditions Chemically-Induced Disorders, Cutaneous Adverse Drug Reactions (CADR), Dermatitis, +17 more Locations Reference Center for Toxic, Toxin and Toxidermal Bullous Dermatoses - E. Herriot Hospital — Lyon, France View Trial Details
Completed Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN NCT06474078 Conditions Chemically-Induced Disorders, Dermatitis, Drug Eruptions, +15 more Locations Chang Gung Memorial Hospital — Taoyuan, Taiwan View Trial Details
Completed Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. NCT01696500 Conditions Chemically-Induced Disorders, Dermatitis, Drug Eruptions, +15 more Locations Nihon Pharmaceutical Co., Ltd — Tokyo, Japan View Trial Details
